Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Working Capital Changes (2022 - 2025)

Historic Other Working Capital Changes for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$64000.0.

  • Corvus Pharmaceuticals' Other Working Capital Changes rose 8150.29% to -$64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 14629.51%. This contributed to the annual value of $1.6 million for FY2024, which is 22933.99% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Other Working Capital Changes of -$64000.0 as of Q3 2025, which was up 8150.29% from $87000.0 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $2.6 million during Q4 2024, with a 5-year trough of -$2.1 million in Q4 2023.
  • Over the past 4 years, Corvus Pharmaceuticals' median Other Working Capital Changes value was -$64000.0 (recorded in 2025), while the average stood at -$122066.7.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first skyrocketed by 22193.64% in 2024, then tumbled by 24970.06% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Other Working Capital Changes (Quarter) stood at -$1.8 million in 2022, then fell by 17.28% to -$2.1 million in 2023, then skyrocketed by 221.94% to $2.6 million in 2024, then plummeted by 102.45% to -$64000.0 in 2025.
  • Its Other Working Capital Changes was -$64000.0 in Q3 2025, compared to $87000.0 in Q2 2025 and -$1.2 million in Q1 2025.